Project description:Our experiment is to compare Glyco-gene expression by interferon-gamma/TNF-treated human corneal epithelial cells also treated either with cell communication glycoprotein 'lacritin' or negative control deletion construct 'C-25 lacritin'. In a newly developing story, lacritin but not C-25 protects human corneal epithelial cells from INFG/TNF-induced cell death. This expression array will help work out the mechanism of protection to complement phosphoblotting and shRNA approaches currently underway. Lacritin targets its coreceptor 'syndecan-1' in lacritin-dependent cell proliferation and secretion. Lacritin appears to be important in human 'dry eye' and in promoting corneal epithelial cell survival in the presence of inflammatory cytokines.
Project description:Our experiment is to compare Glyco-gene expression by interferon-gamma/TNF-treated human corneal epithelial cells also treated either with cell communication glycoprotein 'lacritin' or negative control deletion construct 'C-25 lacritin'. In a newly developing story, lacritin but not C-25 protects human corneal epithelial cells from INFG/TNF-induced cell death. This expression array will help work out the mechanism of protection to complement phosphoblotting and shRNA approaches currently underway.
Project description:RNA from cultured human bronchial epithelial cells treated for 8 hours or for 24 hours with medium alone, interferon gamma, dexamethasone or both interferon gamma and dexamethasone. Keywords = interferon gamma Keywords = dexamethasone Keywords = human bronchial epithelial cells Keywords: dose response
Project description:RNA from cultured human bronchial epithelial cells treated for 8 hours or for 24 hours with medium alone, interferon gamma, dexamethasone or both interferon gamma and dexamethasone.
Project description:Gene expression profiling of immortalized human mesenchymal stem cells with hTERT/E6/E7 transfected MSCs. hTERT may change gene expression in MSCs. Goal was to determine the gene expressions of immortalized MSCs.
